Do you want to read an article? Please log in or register.
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
Related content
COMMENTED
Glycemic Control
Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study
Diabetes Care.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG
doi: 10.2337/dc18-0287.
Diabetes - General
Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study
Diabetes Care.
Cho J, Scragg R, Pandol SJ, Goodarzi MO, Petrov MS
doi: 10.2337/dc19-0145.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Ann Intern Med.
Madenidou AV, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, Bekiari E, Matthews DR, Tsapas A
doi: 10.7326/M18-0443.
Obesity and Bariatric Surgery
Adolescent obesity and midlife cancer risk: a population-based cohort study of 2·3 million adolescents in Israel
Lancet Diabetes Endocrinol.
Furer A, Afek A, Sommer A, Keinan-Boker L, Derazne E, Levi Z, Tzur D, Tiosano S, Shina A, Glick Y, Kark JD, Tirosh A, Twig G
doi: 10.1016/S2213-8587(20)30019-X.
Type 2 Diabetes
Cumulative Risk of End-Stage Renal Disease Among Patients With Type 2 Diabetes: A Nationwide Inception Cohort Study
Diabetes Care.
Finne P, Groop PH, Arffman M, Kervinen M, Helve J, Grönhagen-Riska C, Sund R
doi: 10.2337/dc18-1485.
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
Type 2 Diabetes
Sodium-glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis - A Multi-site Prevalent New-user Cohort Study
Diabetes Obes Metab.
Fisher A, Fralick M, Filion KB, Dell'Aniello S, Douros A, Tremblay É, Shah BR, Ronksley PE, Alessi-Severini S, Hu N, Bugden SC, Ernst P, Lix LM, Canadian Network for Observational Drug Effect Studies (CNODES).
doi: 10.1111/dom.14082.
Glycemic Control
Comparative effects of sulfonylureas, DPP4is and SGLT2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care
Diabetes Obes Metab.
Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel-Farrant H, Smeeth L, Douglas IJ, Tomlinson LA
doi: 10.1111/dom.13970.
Type 1 Diabetes
Single-dose euglycemic clamp study in two cohorts to compare exposure of SAR341402 (insulin aspart) Mix 70/30 to US- and EU-Approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes
Diabetes Obes Metab
Kapitza C, Nosek L, Schmider W, Teichert L, Mukherjee B, Nowotny I
doi: 10.1111/dom.14260